Janux Therapeutics Inc. (JANX) NASDAQ
$48.85 - (-)
Market Cap: $2.52B
As of 04/18/24 12:00 AM EDT. Market open.
Janux Therapeutics Inc. (JANX)
NASDAQ
$48.85
- (-)
Market Cap: $2.52B
As of 04/18/24 12:00 AM EDT. Market open.
janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug ... read more
janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug targets. while tce therapeutics have displayed potent anti-tumor activity in hematological cancers, developing tces to treat solid tumors have faced challenges due to the limitations of prior tce technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. janux is using its tractr platform technology to engineer product candidates designed to overcome these limitations. janux is developing a broad pipeline with lead programs targeting prostate-specific membr read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Reardon Tighe | Acting Chief Financial Officer | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 15, 2023, 04:48 PM |
Lichter Jay | Director | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 15, 2023, 04:46 PM |
Avalon Ventures XI, L.P. | 10% Owner | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 13, 2023, 07:11 PM |
RA CAPITAL MANAGEMENT, L.P. | Director | Jul 19, 2023 | Buy | $12.46 | 495,008 | 6,167,800 | 8,117,246 | Jul 21, 2023, 04:31 PM |
ORBIMED ADVISORS LLC | Director | Dec 29, 2021 | Sale | $20.30 | 40,400 | 820,120 | 2,258,566 | Dec 30, 2021, 09:00 PM |
Thompson Peter A. | Director | Dec 29, 2021 | Sale | $20.30 | 40,400 | 820,120 | 2,258,566 | Dec 30, 2021, 08:55 PM |
ORBIMED ADVISORS LLC | Director | Dec 21, 2021 | Sale | $19.00 | 119,400 | 2,268,600 | 2,295,266 | Dec 23, 2021, 04:13 PM |
Thompson Peter A. | Director | Dec 21, 2021 | Sale | $19.00 | 119,400 | 2,268,600 | 2,295,266 | Dec 23, 2021, 04:08 PM |
Thompson Peter A. | Director | Dec 16, 2021 | Sale | $19.07 | 393,300 | 7,500,231 | 2,403,566 | Dec 17, 2021, 05:16 PM |
ORBIMED ADVISORS LLC | Director | Dec 16, 2021 | Sale | $19.07 | 393,300 | 7,500,231 | 2,403,566 | Dec 17, 2021, 05:13 PM |
Thompson Peter A. | Director | Jun 15, 2021 | Buy | $17.00 | 705,853 | 11,999,501 | 2,760,366 | Jun 16, 2021, 06:20 PM |
Reardon Tighe | Acting Chief Financial Officer | Jun 15, 2021 | Buy | $17.00 | 629,411 | 10,699,987 | 4,479,492 | Jun 16, 2021, 06:11 PM |
Owner | Relationship | Date | Value($) |
Reardon Tighe | Acting Chief Financial Officer | 11/13/2023 | 4,988,643 |
Lichter Jay | Director | 11/13/2023 | 4,988,643 |
Avalon Ventures XI, L.P. | 10% Owner | 11/13/2023 | 4,988,643 |
RA CAPITAL MANAGEMENT, L.P. | Director | 07/19/2023 | 6,167,800 |
ORBIMED ADVISORS LLC | Director | 12/29/2021 | 820,120 |
Thompson Peter A. | Director | 12/29/2021 | 820,120 |
ORBIMED ADVISORS LLC | Director | 12/21/2021 | 2,268,600 |
Thompson Peter A. | Director | 12/21/2021 | 2,268,600 |
Thompson Peter A. | Director | 12/16/2021 | 7,500,231 |
ORBIMED ADVISORS LLC | Director | 12/16/2021 | 7,500,231 |
Thompson Peter A. | Director | 06/15/2021 | 11,999,501 |
Reardon Tighe | Acting Chief Financial Officer | 06/15/2021 | 10,699,987 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. | 10,593,395 | 7.07% | 15.58% | Other |
ORBIMED ADVISORS LLC | 3,317,927 | 0.71% | No change | Other |
BLACKROCK INC. | 1,762,101 | 0.00048% | 7.47% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,355,475 | 0.03% | 17.87% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 408,190 | 0.00046% | 5.53% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View